Inhibikase Therapeutics
Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.
$2.41
After-hours close−0.00 (−0.21%)
At close$2.42(−2.23%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 86.34%113.99M sharesInsiders 1.23%1.62M sharesOther 12.43%16.42M shares
Shares outstanding 132.03M · Float —
Institutions13F, as of Mar 31, 2026
104 holders · 113.99M shares · 40 new positions · 77 increased · 14 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Sands Capital Ventures, LLC | 13.02M | 9.86% | 0 | May 8, 2026 |
| Soleus Capital Management, L.P. | 10.88M | 8.24% | 0 | May 14, 2026 |
| Fairmount Funds Management LLC | 8.63M | 6.53% | 0 | May 15, 2026 |
| Trails Edge Capital Partners, LP | 8.06M | 6.10% | +1.88M | May 15, 2026 |
| Adar1 Capital Management, LLC | 6.61M | 5.00% | −1.46M | May 18, 2026 |
| BlackRock, Inc. | 6.30M | 4.77% | +3.00M | May 13, 2026 |
| Blackstone Inc. | 5.94M | 4.50% | 0 | May 15, 2026 |
| Siren, L.L.C. | 5.85M | 4.43% | 0 | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sands Capital Ventures, LLCincl. Frank M. Sands, Sands Capital Life Sciences Pulse Fund II, L.P. | 16.30% | 10.95M | 13G | Oct 25, 2024 ↗ |
| RA Capital Management, L.P. | 15.90% | 25.00M | 13G | Jul 17, 2026 ↗ |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10.80% | 13.02M | 13G | Feb 13, 2026 ↗ |
| Steven Boydincl. Armistice Capital, LLC | 9.99% | Nov 14, 2024 ↗ | ||
| Soleus Private Equity Fund III, L.P.incl. Soleus Capital Master Fund, L.P., Soleus Capital Group, LLC +5 more | 9.99% | 7.23M | 13G | Oct 28, 2024 ↗ |
| Perceptive Life Sciences Master Fund, Ltd.incl. Perceptive Advisors LLC, Joseph Edelman | 9.99% | 6.80M | 13G | Oct 22, 2024 ↗ |
| Capital Master LPincl. Capital LP | 9.99% | 6.81M | 13G | Oct 17, 2024 ↗ |
| ADAR1 Capital Management, LLC | 9.90% | 13.86M | 13G | May 15, 2026 ↗ |
| Commodore Capital LP | 9.90% | 14.05M | 13G | May 15, 2026 ↗ |
| Fairmount Funds Management LLC | 9.90% | 12.46M | 13G | Feb 17, 2026 ↗ |
| Peter Harwinincl. Tomas Kiselak, Fairmount Healthcare Fund II L.P. +1 more | 9.90% | 6.62M | 13G | Oct 17, 2024 ↗ |
| Perceptive Advisors LLC | 8.90% | 12.64M | 13G | May 15, 2026 ↗ |
| LLCincl. Holdings LLC | 8.69% | 5.84M | 13G | Oct 28, 2024 ↗ |
| Point72 Capital Advisors, Inc.incl. Steven A. Cohen, Point72 Asset Management, L.P. | 8.40% | 13G | Oct 10, 2024 ↗ | |
| Trails Edge Capital Partners, LP | 6.10% | 8.06M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 13.02M | 9.86% | Nov 24, 2025 |
| Ra Capital Management, L.P. | 10 percent owner | 6.97M | 5.28% | Jul 31, 2026 |
| Christopher Cabell | officer: President & Head of R&D | 676.6K | 0.51% | Feb 24, 2026 |
| Vincent Aurentz | director | 510.6K | 0.39% | Feb 24, 2026 |
| Amit Munshi | director | 403.2K | 0.31% | Feb 24, 2026 |
| Dennis N. Berman | director | 21.9K | 0.02% | Jul 31, 2026 |
| David McIntyre | officer: Chief Financial Officer | 10.3K | 0.01% | Apr 16, 2025 |
2 ten-percent owners hold 19.99M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 4 people have not refiled in the last 18 months (2.50M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P.10 percent owner | Purchase | 2,068,965 | $1.45 | 13,018,965 |
CongressHouse and Senate disclosures
Not reported.